|
[PMID]: | 28746570 |
[Au] Autor: | Shikanai-Yasuda MA; Mendes RP; Colombo AL; Queiroz-Telles F; Kono ASG; Paniago AMM; Nathan A; Valle ACFD; Bagagli E; Benard G; Ferreira MS; Teixeira MM; Silva-Vergara ML; Pereira RM; Cavalcante RS; Hahn R; Durlacher RR; Khoury Z; Camargo ZP; Moretti ML; Martinez R |
[Ad] Endereço: | Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. |
[Ti] Título: | Brazilian guidelines for the clinical management of paracoccidioidomycosis. |
[So] Source: | Rev Soc Bras Med Trop;50(5):715-740, 2017 Sep-Oct. | [Is] ISSN: | 1678-9849 |
[Cp] País de publicação: | Brazil |
[La] Idioma: | eng |
[Ab] Resumo: | Paracoccidioidomycosis is a systemic fungal disease occurring in Latin America that is associated with rural environments and agricultural activities. However, the incidence and prevalence of paracoccidiodomycosis is underestimated because of the lack of compulsory notification. If paracoccidiodomycosis is not diagnosed and treated early and adequately, the endemic fungal infection could result in serious sequelae. While the Paracoccidioides brasiliensis ( P. brasiliensis ) complex has been known to be the causal agent of paracoccidiodomycosis, a new species, Paracoccidioides lutzii ( P. lutzii ), has been reported in Rondônia, where the disease has reached epidemic levels, and in the Central West and Pará. Accurate diagnoses and availability of antigens that are reactive with the patients' sera remain significant challenges. Therefore, the present guidelines aims to update the first Brazilian consensus on paracoccidioidomycosis by providing evidence-based recommendations for bedside patient management. This consensus summarizes etiological, ecoepidemiological, molecular epidemiological, and immunopathological data, with emphasis on clinical, microbiological, and serological diagnosis and management of clinical forms and sequelae, as well as in patients with comorbidities and immunosuppression. The consensus also includes discussion of outpatient treatments, severe disease forms, disease prevalence among special populations and resource-poor settings, a brief review of prevention and control measures, current challenges and recommendations. |
[Mh] Termos MeSH primário: |
Antifúngicos/uso terapêutico Gerenciamento Clínico Paracoccidioidomicose/tratamento farmacológico Paracoccidioidomicose/patologia
|
[Mh] Termos MeSH secundário: |
Brasil Consenso Diagnóstico Diferencial Seres Humanos Itraconazol/uso terapêutico América Latina Paracoccidioides
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; PRACTICE GUIDELINE |
[Nm] Nome de substância:
| 0 (Antifungal Agents); 304NUG5GF4 (Itraconazole) |
[Em] Mês de entrada: | 1712 |
[Cu] Atualização por classe: | 171218 |
[Lr] Data última revisão:
| 171218 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170727 |
[St] Status: | MEDLINE |
|
|
|